Market-Moving News for April 9th
$ACRV
$LASE
$VVOS
Biotechnology: Pharmaceutical Preparations
Health Care
Industrial Machinery/Components
Miscellaneous
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 9/16/2024 | $16.00 | Neutral → Buy | Ladenburg Thalmann | |
| 4/29/2024 | Buy → Neutral | Ladenburg Thalmann | ||
| 3/1/2024 | $14.00 | Mkt Outperform | JMP Securities | |
| 12/15/2023 | $17.00 → $12.00 | Buy | Jefferies | |
| 10/5/2023 | Buy | Maxim Group | ||
| 6/2/2023 | $25.00 | Outperform | Oppenheimer | |
| 5/8/2023 | $25.00 | Outperform | BMO Capital Markets | |
| 4/27/2023 | $22.00 | Buy | Ladenburg Thalmann |
Revenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today reported financial results and operating highlights for the third quarter and nine months ended September 30, 2024.
Laser Photonics Corporation (NASDAQ:LASE), ("LPC"), a leading global developer of CleanTech laser systems for laser cleaning and other material applications, today announced results for its third quarter ended September 30, 2024. Wayne Tupuola, CEO of Laser Photonics, commented on the third quarter: "Looking at the quarter, we navigated a challenging period marked by increased investment in HR, Sales, and administrative functions—strategic moves that, while impacting our short-term performance, are essential for our future growth. We also secured several key deals, such as a sale of our CleanTech Industrial Roughening Laser 3050 to Acuren, another sale to the U.S. Navy, and an expansion
LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. Vivos' management will conduct a conference call at 5:00 p.m. (Eastern Time) on November 14, 2024 to review the results and provide an overview of Vivos' recent achievements and developments. To
Laser Photonics Corporation (NASDAQ: LASE) (LPC), a leading global developer of laser systems for cleaning and other material processing applications, announced today that it has appointed John T. Armstrong as its new Executive Vice President. Prior to joining Laser Photonics, Armstrong served as a Vice President for Astronics Test Systems (ATS), a subsidiary of Astronics Corporation, a leading supplier of advanced technologies and products to the global aerospace, defense and other mission-critical industries. Previously, he served as a Senior Manager for Boeing, providing leadership and HR support for 10,000+ employees nationwide within a division that generated $4.5B+ in revenue. Earli
Showcasing Cutting-Edge Laser Solutions For Global Mining Industry Laser Photonics Corporation (LPC) (NASDAQ:LASE), a leading global developer of industrial laser systems for laser cleaning and other material processing applications, is to join Brokk Australia at the International Mining and Resources Conference (IMARC), a top forum for critical discussions and innovation across the global mining and resources sector. In its 11th year, Australia's largest mining event, IMARC 2024, prepares to open its doors to more than 9,000 attendees from 120 countries at the ICC Sydney Convention Center from October 29 to 31. This year, LPC and Brokk Australia will be among over 500 companies showcasin
Laser Photonics Corporation (NASDAQ:LASE) (LPC), a leading global developer of laser systems for cleaning and other material processing applications, announced today that it has appointed Robert Hoffman as its new Outside Sales Director as part of its long-term growth and diversification strategy. Prior to joining Laser Photonics, Hoffman served as the Southeast Regional Sales Manager for Keyence, a leading provider of factory automation solutions, including sensors, measuring systems, laser markers, microscopes, and machine vision systems. He also held the role of Project Manager at Easy Imex, assisting businesses from Australia, the United Kingdom, the United States, and Europe in import
Laser Photonics Corporation (NASDAQ: LASE) (LPC), a leading global developer of laser systems for cleaning and other material processing applications, announced today that it has appointed John T. Armstrong as its new Executive Vice President. Prior to joining Laser Photonics, Armstrong served as a Vice President for Astronics Test Systems (ATS), a subsidiary of Astronics Corporation, a leading supplier of advanced technologies and products to the global aerospace, defense and other mission-critical industries. Previously, he served as a Senior Manager for Boeing, providing leadership and HR support for 10,000+ employees nationwide within a division that generated $4.5B+ in revenue. Earli
Revenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today reported financial results and operating highlights for the third quarter and nine months ended September 30, 2024.
Laser Photonics Corporation (NASDAQ:LASE), ("LPC"), a leading global developer of CleanTech laser systems for laser cleaning and other material applications, today announced results for its third quarter ended September 30, 2024. Wayne Tupuola, CEO of Laser Photonics, commented on the third quarter: "Looking at the quarter, we navigated a challenging period marked by increased investment in HR, Sales, and administrative functions—strategic moves that, while impacting our short-term performance, are essential for our future growth. We also secured several key deals, such as a sale of our CleanTech Industrial Roughening Laser 3050 to Acuren, another sale to the U.S. Navy, and an expansion
Governor Ron DeSantis went there at the Republican National Convention (RNC) in Milwaukee on Wednesday: He used his platform to rail against Florida's upcoming vote to legalize recreational marijuana telling his comrades that if weed is legalized, people will be able to possess practically limitless amounts of the stuff. "It gives you a limitless constitutional right to possess and smoke. I think it's up to like, what, 40 joints, is that the three ounces would be 40? More than that, 80 joints. Something like that," he said. In fact, he noted that if the cannabis legalization ballot wins, marijuana rights will surpass the constitutional guarantees of the First and Second Amendments
4 - Laser Photonics Corp (0001807887) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
Ladenburg Thalmann upgraded Acrivon Therapeutics from Neutral to Buy and set a new price target of $16.00
Ladenburg Thalmann downgraded Acrivon Therapeutics from Buy to Neutral
JMP Securities initiated coverage of Acrivon Therapeutics with a rating of Mkt Outperform and set a new price target of $14.00
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
10-Q - Laser Photonics Corp (0001807887) (Filer)
8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
10-Q - Vivos Therapeutics, Inc. (0001716166) (Filer)
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)
